MedBulletinsAura Celeste
Oncology

What's next in oncology — November 14, 2026

🎧 Listen to this issueAudio newscast · 3:19 min

This issue brings together four oncology milestones with verifiable dates between November 30, 2026 and April 9, 2027: three FDA decisions (PDUFA target dates announced by the companies) and full data from two phase 3 trials at the San Antonio Breast Cancer Symposium. A PDUFA date does not guarantee approval: the FDA may approve, reject (complete response letter) or extend the review.

1. Bezuclastinib + sunitinib in second-line GIST

[Pending regulatory decision] [United States] [Confirmed date: November 30, 2026]
What it is: NDA under priority review based on PEAK (randomized, open-label phase 3, NCT05208047), 413 patients with advanced GIST who progressed on or were intolerant to imatinib, randomized to bezuclastinib + sunitinib vs sunitinib alone; median PFS by blinded central review 16.5 vs 9.2 months (HR 0.50; 95% CI 0.39–0.65) and objective response 45.6% vs 25.8% (data presented at ASCO 2026).
What problem it solves: after imatinib, the standard is sunitinib monotherapy, with limited benefit because of secondary KIT mutations; the combination aims to cover that resistance spectrum.
Critical take: open-label trial developed by Cogent, with immature OS (under 20% events, crossover allowed after centrally confirmed progression) and more liver toxicity (ALT/AST elevation 56.4% vs 16.8%; grade ≥3 10.8% vs 1.4%).

Sources

2. SABCS 2026: full SERENA-4 data and final EMBER-3 OS

[Congress] [United States (San Antonio), global reach] [Confirmed date: December 11, 2026]
What it is: General Session 3 (symposium December 8–11) features SERENA-4 (NCT04711252; randomized, double-blind phase 3; 1,371 patients according to AstraZeneca, camizestrant + palbociclib vs anastrozole + palbociclib as first-line therapy for ER+/HER2− advanced breast cancer, primary endpoint investigator-assessed PFS) and final overall survival from EMBER-3 (imlunestrant vs standard of care in ESR1-mutated advanced breast cancer).
What problem it solves: determines whether an oral SERD should replace the aromatase inhibitor up front rather than be reserved for progression or emergence of an ESR1 mutation.
Critical take: AstraZeneca has already announced that SERENA-4 did not meet its primary PFS endpoint (with a numerical improvement, no figures released), so the presentation is for the size of the effect, subgroups and safety, not for changing the current standard.

Sources

3. Zanzalintinib + atezolizumab in pretreated metastatic colorectal cancer

[Pending regulatory decision] [United States] [Confirmed date: March 3, 2027]
What it is: NDA based on STELLAR-303 (randomized, open-label phase 3, NCT05425940, 901 patients without MSI-H/dMMR, vs regorafenib); median OS in the intention-to-treat population 10.9 vs 9.4 months (HR 0.80; 95% CI 0.69–0.93). The FDA extended the deadline by three months, from December 3, 2026, after classifying as a major amendment the updated data Exelixis submitted in response to an information request.
What problem it solves: in third line and beyond, the options (regorafenib, trifluridine/tipiracil ± bevacizumab, fruquintinib) offer modest benefit, and immunotherapy does not work in microsatellite-stable tumors.
Critical take: absolute gain of about 1.5 months in an open-label Exelixis trial; the co-primary endpoint in patients without liver metastases was not significant (HR 0.79; 95% CI 0.61–1.03).

Sources

4. Rivoceranib + camrelizumab as first-line therapy for hepatocellular carcinoma

[Pending regulatory decision] [United States] [Confirmed date: April 9, 2027]
What it is: resubmission (October 9, 2026) of the rivoceranib NDA (Elevar) and camrelizumab BLA (Hengrui), under integrated review, based on CARES-310 (phase 3, NCT03764293, 543 patients, vs sorafenib): median OS 23.8 vs 15.2 months (HR 0.64; 95% CI 0.52–0.79).
What problem it solves: broadens first-line combination options (oral VEGFR inhibitor + anti-PD-1) for unresectable or metastatic hepatocellular carcinoma.
Critical take: the comparator (sorafenib) is no longer the standard against atezolizumab-bevacizumab or durvalumab-tremelimumab; this is the fourth submission after three complete response letters, and the latest (July 2026) was due, according to Elevar, to deficiencies found in a cGMP inspection of a manufacturing site, not to efficacy.

Sources

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.